Clinical trial

Neurotransmitters in Treatment Resistant Schizophrenia Patients With add-on Sodium Benzoate

NCT06340789

Study summary

ClinicalTrials.gov

Neurotransmitters in Treatment Resistant Schizophrenia Patients With add-on Sodium Benzoate

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Sodium Benzoate 2gram/day Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2021-11-18

PhasePHASE2

Conditions

Symptom, Cognitiveunresolved

Schizophreniaverified · MONDO: schizophrenia

Schizo Affective Disorderunresolved

Interventions

Sodium Benzoate 2gram/dayDRUG

PlaceboDRUG

Sponsors & collaborators

National Cheng-Kung University Hospitallead sponsor

Mapped research locations

Chiayi CityTaiwan1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06340789 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.